CTSO

#4127
Cytosorbents Corporation - Common Stock
0.4 9 USD
+2.08%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
0.49
0.49
Yıllık Aralık
0.44
1.39
Günlük Değişim
+2.08%
Aylık Değişim
-20.97%
6 Aylık Değişim
-40.24%
Yıllık Değişim
-41.67%
Önceki Kapanış
0.4 8
Open
0.4 9
Düşük
0.4 9
High
0.4 9
Hacim
4
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 30.77 M
  • Employee 129
  • Founded 1997
  • CEO N/A
  • Website www.cytosorbents.com
  • Headquarter Delaware, United States
  • FIGI BBG000C3P8V0
  • Industry Tıbbi Cihazlar
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
-4.92
Fiyat/satışlar oranı
1.07

Cytosorbents Corporation - Common Stock

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.

Haberler